"What we've all been waiting for" is how H.C. Wainwright analyst Joseph Pantginis characterized details about the successful end-of-phase-II meeting with the FDA disclosed by Iovance Biotherapeutics Inc., news that helped the San Carlos, Calif.-based company raise $219.3 million through a stock sale.